

# Pharmacological and chemogenetic investigations of 5-HT<sub>2C</sub> receptor function in rodent touchscreen visual reversal learning



Nilsson, SRO.<sup>1,2</sup>, Alsio, J.<sup>1,2,3</sup>, Gastambide, F.<sup>4</sup>, Wang, RAH.<sup>1,2</sup>, Dam, SA.<sup>1,2</sup>, Mar, AC.<sup>1,2</sup>, Saksida, LM.<sup>1,2</sup>, Tricklebank, M.<sup>4</sup>, Bussey, TJ.<sup>1,2</sup>, Heisler, LK<sup>5</sup>, & Robbins, TW.<sup>1,2</sup>

<sup>1</sup>Department of Psychology, University of Cambridge <sup>2</sup>Behavioural and Clinical Neuroscience Institute, University of Cambridge. <sup>3</sup>Department of Neuroscience, University of Uppsala. <sup>4</sup>Lilly Centre for Cognitive Neuroscience, Eli Lilly & Co. Ltd. <sup>5</sup>Rowett Institute of Nutrition and Health, University of Aberdeen

## BACKGROUND

Reversal learning deficits are observed in psychiatric disorders such as schizophrenia and obsessive-compulsive disorder and implicate neural circuitry including the orbitofrontal cortex (OFC) and activity at 5-HT<sub>2C</sub> receptors (5-HT<sub>2C</sub>R) in this area. In the current experiments, we developed a novel battery of touchscreen reversal learning tasks and used pharmacological and chemogenetic manipulations to assess the role of 5-HT<sub>2C</sub>R activity in reversal learning in rats and mice.

## METHODS

**Experiment 1** assessed effects of systemic SB242084 in 2-stimulus reversal learning in the rat.


**Experiment 2** investigated effects of systemic SB242084 in 3-stimulus reversal learning in the rat.

**Experiment 3** assessed effects intra-OFC baclofene/muscimol infusion on a novel serial visual reversal task in the rat.

**Experiment 4** assessed effects intra-OFC SB242084 infusion on serial visual reversal task in the rat.


**Experiment 5** assessed effects intra-OFC rM3DS-infusion in 5-HT<sub>2C</sub>-Cre positive and negative mice in 2-stimulus reversal learning

## Systemic 5-HT<sub>2C</sub>R antagonism 2-choice reversal learning




★ **EXPERIMENT 1: Systemic SB242084 improved early learning and impaired late learning in the 2-stimulus task**

## Systemic 5-HT<sub>2C</sub>R antagonism 3-choice reversal learning




★ **EXPERIMENT 2: Systemic SB242084 improved early learning and impaired late learning in the 3-stimulus task. Effects were observed in labs of both academic and industrial collaborators**

## OFC inactivation 2-choice serial reversal learning




★ **EXPERIMENT 3: Intra-OFC baclofen / muscimol impaired early learning without affecting late learning in the 2-stimulus serial reversal task**

## Intra-OFC 5-HT<sub>2C</sub>R antagonism 2-choice serial reversal learning



★ **EXPERIMENT 4: Intra-OFC SB242084 infusion improved early learning without affecting late learning in the 2-stimulus serial reversal task**

## Intra-OFC rM3Ds / 5-HT<sub>2C</sub>-Cre 2-choice reversal learning



★ **EXPERIMENT 5: Systemic clozapine-N-oxide (3 mg/kg, i.p.) impaired early reversal learning without affecting late reversal learning in intra-OFC rM3Ds treated 5-HT<sub>2C</sub> Cre-positive mice.**

## CONCLUSIONS

We used pharmacological (systemic and intra-OFC) and chemogenetic (intra-OFC rM3Ds infusion/ HT2CCre mice) manipulations to show that activity at the OFC 5-HT<sub>2C</sub>Rs counteracts maladaptive perseverative responding in a novel, touch-screen controlled, visual reversal learning task for rodents. Normal performance on the reversal task was also shown to depend on OFC function, following its muscimol-induced inactivation. These data on the role of 5HT<sub>2C</sub>Rs extend earlier evidence that OFC 5-HT plays an important role in cognitive flexibility (e.g., Clarke et al. Science 2004; 304: 878–880), possibly relevant to human OCD. Systemic treatment with the 5-HT<sub>2C</sub>R antagonist additionally impaired late reversal learning (though without impairing discrimination learning), an effect of interference presumably mediated at sites other than the OFC.

## ACKNOWLEDGEMENTS

This work was supported by Wellcome Trust Senior Investigator Award (104631/Z/14/Z) awarded to T.W. Robbins. Johan Alsio is supported by the Swedish Pharmaceutical Society and the Swedish Research Council (350-2012-230).